Sihuan Pharmaceutical Holdings Group Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Sihuan Pharmaceutical Holdings Group (HKG:460) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥1.86b (down 15% from FY 2022).
• Net loss: CN¥54.0m (loss narrowed by 97% from FY 2022).
• CN¥0.006 loss per share (improved from CN¥0.21 loss in FY 2022).

460 Products In Clinical Trials

• Phase I: 8.
• Phase II: 3.
• Phase III: 2.

460 Post-Clinical Trial Products

• Pre-registration: 3.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sihuan Pharmaceutical Holdings Group EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 21%. Earnings per share (EPS) exceeded analyst estimates by 48%.

The primary driver behind last 12 months revenue was the Generic Medicine segment contributing a total revenue of CN¥1.40b (75% of total revenue). The largest operating expense was Research & Development (R&D) costs, amounting to CN¥577.7m (40% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of CN¥86.5m. Explore how 460's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are up 9.8% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Sihuan Pharmaceutical Holdings Group's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.